A practical guide to the management of hcv infection following liver transplantation

K. Watt, B. Veldt, M. Charlton

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Hepatitis C-associated liver failure is the most common indication for liver transplantation, with virological recurrence near ubiquitous. Approximately 30% of HCV-infected recipients will die or lose their allograft or develop cirrhosis secondary to hepatitis C recurrence by the fifth postoperative year, with the proportion increasing with duration of follow-up. Strategies for minimizing the frequency of severe HCV recurrence include avoidance of older donors, early diagnosis/treatment of CMV and minimization of immunosuppression, particularly T-cell depleting therapies and pulsed corticosteroid treatment of acute cellular rejection. Patients should be offered treatment with peginterferon and ribavirin before LT if MELD ≤ 17 or as soon as histological evidence of recurrence of HCV is apparent post-LT. Because of the high frequency of hemotoxicity and renal insufficiency, ribavirin should be dosed according to renal function.

Original languageEnglish (US)
Pages (from-to)1707-1713
Number of pages7
JournalAmerican Journal of Transplantation
Volume9
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Liver Transplantation
Recurrence
Ribavirin
Hepatitis C
Infection
Liver Failure
Cell- and Tissue-Based Therapy
Immunosuppression
Renal Insufficiency
Allografts
Early Diagnosis
Adrenal Cortex Hormones
Fibrosis
Therapeutics
Tissue Donors
T-Lymphocytes
Kidney

Keywords

  • HCV
  • Immunosuppression
  • Liver transplantation
  • Recurrence
  • Treatment

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

A practical guide to the management of hcv infection following liver transplantation. / Watt, K.; Veldt, B.; Charlton, M.

In: American Journal of Transplantation, Vol. 9, No. 8, 08.2009, p. 1707-1713.

Research output: Contribution to journalArticle

Watt, K. ; Veldt, B. ; Charlton, M. / A practical guide to the management of hcv infection following liver transplantation. In: American Journal of Transplantation. 2009 ; Vol. 9, No. 8. pp. 1707-1713.
@article{afc378a8c0f3434fb5519525e4c9249b,
title = "A practical guide to the management of hcv infection following liver transplantation",
abstract = "Hepatitis C-associated liver failure is the most common indication for liver transplantation, with virological recurrence near ubiquitous. Approximately 30{\%} of HCV-infected recipients will die or lose their allograft or develop cirrhosis secondary to hepatitis C recurrence by the fifth postoperative year, with the proportion increasing with duration of follow-up. Strategies for minimizing the frequency of severe HCV recurrence include avoidance of older donors, early diagnosis/treatment of CMV and minimization of immunosuppression, particularly T-cell depleting therapies and pulsed corticosteroid treatment of acute cellular rejection. Patients should be offered treatment with peginterferon and ribavirin before LT if MELD ≤ 17 or as soon as histological evidence of recurrence of HCV is apparent post-LT. Because of the high frequency of hemotoxicity and renal insufficiency, ribavirin should be dosed according to renal function.",
keywords = "HCV, Immunosuppression, Liver transplantation, Recurrence, Treatment",
author = "K. Watt and B. Veldt and M. Charlton",
year = "2009",
month = "8",
doi = "10.1111/j.1600-6143.2009.02702.x",
language = "English (US)",
volume = "9",
pages = "1707--1713",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - A practical guide to the management of hcv infection following liver transplantation

AU - Watt, K.

AU - Veldt, B.

AU - Charlton, M.

PY - 2009/8

Y1 - 2009/8

N2 - Hepatitis C-associated liver failure is the most common indication for liver transplantation, with virological recurrence near ubiquitous. Approximately 30% of HCV-infected recipients will die or lose their allograft or develop cirrhosis secondary to hepatitis C recurrence by the fifth postoperative year, with the proportion increasing with duration of follow-up. Strategies for minimizing the frequency of severe HCV recurrence include avoidance of older donors, early diagnosis/treatment of CMV and minimization of immunosuppression, particularly T-cell depleting therapies and pulsed corticosteroid treatment of acute cellular rejection. Patients should be offered treatment with peginterferon and ribavirin before LT if MELD ≤ 17 or as soon as histological evidence of recurrence of HCV is apparent post-LT. Because of the high frequency of hemotoxicity and renal insufficiency, ribavirin should be dosed according to renal function.

AB - Hepatitis C-associated liver failure is the most common indication for liver transplantation, with virological recurrence near ubiquitous. Approximately 30% of HCV-infected recipients will die or lose their allograft or develop cirrhosis secondary to hepatitis C recurrence by the fifth postoperative year, with the proportion increasing with duration of follow-up. Strategies for minimizing the frequency of severe HCV recurrence include avoidance of older donors, early diagnosis/treatment of CMV and minimization of immunosuppression, particularly T-cell depleting therapies and pulsed corticosteroid treatment of acute cellular rejection. Patients should be offered treatment with peginterferon and ribavirin before LT if MELD ≤ 17 or as soon as histological evidence of recurrence of HCV is apparent post-LT. Because of the high frequency of hemotoxicity and renal insufficiency, ribavirin should be dosed according to renal function.

KW - HCV

KW - Immunosuppression

KW - Liver transplantation

KW - Recurrence

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=67650938551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650938551&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02702.x

DO - 10.1111/j.1600-6143.2009.02702.x

M3 - Article

C2 - 19538491

AN - SCOPUS:67650938551

VL - 9

SP - 1707

EP - 1713

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -